Trial Profile
A PHASE 3, MULTICENTER, FOUR-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY TRIAL OF FLEXIBLE DOSES OF ORAL ZIPRASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR I DISORDER (CURRENT OR MOST RECENT EPISODE MANIC)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Ziprasidone (Primary)
- Indications Bipolar I disorders
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer; Viatris Inc
- 01 Apr 2022 Primary endpoint change from baseline in Young Mania Rating Scale (YMRS) to week 4 has been met, according to results published in the Journal of Child and Adolescent Psychopharmacology.
- 01 Apr 2022 Results published in the Journal of Child and Adolescent Psychopharmacology
- 21 Jul 2020 Status changed from recruiting to discontinued.